Sabine Herblot
Overview
Explore the profile of Sabine Herblot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
688
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Poirier N, Paquin V, Leclerc S, Lisi V, Marmolejo C, Affia H, et al.
J Immunother Cancer
. 2024 May;
12(5).
PMID: 38754915
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) remains the standard of care for chemotherapy-refractory leukemia patients, but cure rates are still dismal. To prevent leukemia relapse following HSCT, we aim...
2.
Veiga D, Tremblay M, Gerby B, Herblot S, Haman A, Gendron P, et al.
Front Immunol
. 2022 Apr;
13:867443.
PMID: 35401501
Early T-cell development is precisely controlled by E proteins, that indistinguishably include HEB/TCF12 and E2A/TCF3 transcription factors, together with NOTCH1 and pre-T cell receptor (TCR) signalling. Importantly, perturbations of early...
3.
Belounis A, Ayoub M, Cordeiro P, Lemieux W, Teira P, Haddad E, et al.
Cancer Immunol Immunother
. 2020 Apr;
69(9):1767-1779.
PMID: 32342128
Targeted immunotherapy has improved the outcome of patients with high-risk neuroblastoma (NB). However, immune escape of tumor cells still occurs and about 40% of NB patients relapse and die from...
4.
Carignan D, Herblot S, Laliberte-Gagne M, Bolduc M, Duval M, Savard P, et al.
Nanomedicine
. 2017 Nov;
14(7):2317-2327.
PMID: 29128662
Rod-shaped virus-like nanoparticles (VLNP) made of papaya mosaic virus (PapMV) coat proteins (CP) self-assembled around a single stranded RNA (ssRNA) were showed to be a TLR7 agonist. Their utilization as...
5.
Terzic T, Cordeau M, Herblot S, Teira P, Cournoyer S, Beaunoyer M, et al.
Pediatr Dev Pathol
. 2017 Oct;
21(4):355-362.
PMID: 29067879
Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with...
6.
Diaz-Rodriguez Y, Cordeiro P, Belounis A, Herblot S, Duval M
Cancer Immunol Immunother
. 2017 May;
66(10):1307-1320.
PMID: 28555259
Acute lymphoblastic leukemia (ALL) is believed to be resistant to NK cell-mediated killing. To overcome this resistance, we developed an innovative approach based on NK cell stimulation with Toll-like receptor...
7.
Cordeau M, Belounis A, Lelaidier M, Cordeiro P, Sartelet H, Herblot S, et al.
PLoS One
. 2016 Oct;
11(10):e0164401.
PMID: 27716850
High-risk neuroblastoma (NB) remains a major therapeutic challenge despite the recent advent of disialoganglioside (GD2)-antibody treatment combined with interleukin (IL)-2 and granulocyte monocyte-colony stimulating factor (GM-CSF). Indeed, more than one...
8.
Lelaidier M, Diaz-Rodriguez Y, Cordeau M, Cordeiro P, Haddad E, Herblot S, et al.
Oncotarget
. 2015 Aug;
6(30):29440-55.
PMID: 26320191
Acute lymphoblastic leukemia (ALL) still frequently recurs after hematopoietic stem cell transplantation (HSCT), underscoring the need to improve the graft-versus-leukemia (GvL) effect. Natural killer (NK) cells reconstitute in the first...
9.
Gerby B, Tremblay C, Tremblay M, Rojas-Sutterlin S, Herblot S, Hebert J, et al.
PLoS Genet
. 2014 Dec;
10(12):e1004768.
PMID: 25522233
The molecular determinants that render specific populations of normal cells susceptible to oncogenic reprogramming into self-renewing cancer stem cells are poorly understood. Here, we exploit T-cell acute lymphoblastic leukemia (T-ALL)...
10.
Charrier E, Cordeiro P, Brito R, Harnois M, Mezziani S, Herblot S, et al.
Biol Blood Marrow Transplant
. 2014 Aug;
20(10):1501-7.
PMID: 25128615
Plasmacytoid dendritic cells (pDCs) initiate both innate and adaptive immune responses, making them attractive targets for post-transplantation immunotherapy, particularly after cord blood transplantation (CBT). Toll-like receptor (TLR) agonists are currently...